Diamines and Chemicals Limited, a Vadodara-based specialty chemicals manufacturer listed on both the BSE (Scrip Code: 500120) and NSE (Symbol: DIAMINESQ), has provided an updated disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The update pertains to a change in senior management involving the resignation of Dr. Piyush Upadhyay, who was serving as the General Manager – Research & Development.

The company had earlier submitted intimations on October 1, 2025 and October 9, 2025, but received a communication from BSE Limited on October 9, 2025, requesting additional details in line with the regulatory requirements prescribed under Clause 7 of Part A of Schedule III of the Listing Regulations and the SEBI Circular dated July 13, 2023 (SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123).

In response, the company has resubmitted the complete disclosure on October 14, 2025, along with Annexure-A, providing all required particulars, including the effective date of cessation, reason for resignation, and supporting documents.

According to the filing, Dr. Piyush Upadhyay resigned from his position with effect from October 1, 2025, citing health-related concerns as the reason for stepping down. The company clarified that the resignation letter was officially submitted on October 9, 2025, as there was a delay in receiving the document from the concerned department due to the unavailability of the reporting personnel.

The resignation letter attached in the disclosure indicates that Dr. Upadhyay originally communicated his decision on August 5, 2025, requesting to be relieved in line with his medical needs. The document also reflects that he acknowledged the support of the management during his tenure and expressed gratitude for the opportunities provided.

An internal note added to the annexure clarifies that following management confirmation, he was relieved from his duties on September 30, 2025, and his cessation took effect from October 1, 2025.

The company has confirmed that this resignation does not involve any director-level position, and hence there are no disclosures relating to board relationships or board appointments. The brief profile and relationship disclosures are marked as not applicable, as this pertains purely to a senior managerial role.

This updated filing ensures regulatory compliance and transparency with both stock exchanges, in adherence to the SEBI LODR framework, which mandates timely and detailed disclosures of key management changes that could impact stakeholders, operations, or governance structures.

The communication was formally signed by Hemaxi Pawar, Company Secretary and Compliance Officer (Membership No. A52581), on behalf of Diamines and Chemicals Limited.

This development reflects the company's commitment to regulatory adherence, corporate disclosure standards, and clarity in communication to shareholders, exchanges, and market participants. The detailed annexure and explanation for the delay in submission underline the organisation’s intent to maintain compliance consistency.

Management changes in strategic roles such as Research & Development are crucial, especially in the chemicals sector, where innovation and process leadership directly influence product development, technology adoption, and long-term competitiveness. Shareholders and analysts may watch for updates regarding the appointment of a successor or interim leadership in the R&D function.

The company has requested both BSE and NSE to take the updated information on record, marking closure of the earlier communication gaps relating to the initial submission.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.